Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art

Ferumoxytol is an ultrasmall iron oxide nanoparticle that was originally approved by the FDA in 2009 for IV treatment of iron deficiency in adults with chronic kidney disease. Subsequently, its off-label use as an MRI contrast agent increased in clinical practice, particularly in pediatric patients in North America. Unlike conventional MRI contrast agents that are based on the rare earth metal gadolinium (gadolinium-based contrast agents), ferumoxytol is biodegradable and carries no potential risk of nephrogenic systemic fibrosis. At FDA-approved doses, ferumoxytol shows no long-term tissue retention in patients with intact iron metabolism. Ferumoxytol provides unique MRI properties, including long-lasting vascular retention (facilitating high-quality vascular imaging) and retention in reticuloendothelial system tissues, thereby supporting a variety of applications beyond those possible with gadolinium-based contrast agents (GBCAs). This Clinical Perspective describes clinical and early translational applications of ferumoxytol-enhanced MRI in children and young adults through off-label use in a variety of settings, including vascular, cardiac, and cancer imaging, drawing on the institutional experience of the authors. In addition, we describe current advances in preclinical and clinical research using ferumoxytol in cellular and molecular imaging as well as the use of ferumoxytol as a novel potential cancer therapeutic agent.

Automated summary

Ferumoxytol is an approved ultrasmall iron oxide nanoparticle that has been increasingly used as an MRI contrast agent, particularly in pediatric patients. Unlike gadolinium-based contrast agents, it is biodegradable and has no potential risk of nephrogenic systemic fibrosis. It has unique MRI properties, including long-lasting vascular retention, making it suitable for various applications, such as vascular, cardiac, and cancer imaging. It is also being researched for its potential use in cellular and molecular imaging and as a potential cancer therapeutic agent.